Older Americans will soon have Medicare access to GLP-1s for weight loss for the first time. Here’s what they need to know.
1 min read
The story
Medicare will begin covering GLP-1 drugs for obesity — not just diabetes — on July 1, with qualifying beneficiaries paying no more than $50 per month out of pocket. This is a landmark policy change: for the first time, the largest U.S. government insurer will explicitly fund weight-loss use of drugs like Eli Lilly's Zepbound (tirzepatide) and Novo Nordisk's Wegovy (semaglutide), covering a population of tens of millions of older Americans who were previously excluded.
For Eli Lilly, which posted $65.2B in revenue with a staggering 44.7% YoY growth and $22.95 diluted EPS, this opens a new demand channel without requiring new approvals. Amgen, reporting $36.8B in revenue at 10% YoY growth, is developing MariTide, an injectable, and has shown early obesity pipeline momentum — though it is not yet on the market with an approved obesity drug.
The bull case rests on volume: Medicare covers roughly 67 million Americans, and obesity prevalence among that cohort is high. Even modest penetration at the $50 cap could translate to significant unit volume and potentially higher reimbursement rates negotiated behind the scenes. Lilly's manufacturing buildout and dominant market position make it the clearest direct beneficiary.
The bear case is more nuanced. The $50/month cap compresses the revenue-per-patient figure that has driven LLY's explosive top-line growth; Medicare price negotiation under the IRA creates ongoing reimbursement pressure. Muscle loss side effects flagged in the article may also dampen uptake among older adults and their physicians. Amgen's pipeline candidate is still pre-commercial, making any near-term uplift speculative.
The key watch items are: (1) actual uptake data beginning Q3 2025, (2) whether the $50 cap materially compresses LLY's GLP-1 ASPs, and (3) Amgen's MariTide Phase 3 readout timeline — a positive result would re-rate AMGN as a credible second player in the Medicare obesity market.
The case — both sides
LLY's 44.7% YoY revenue growth with an already-scaled Zepbound manufacturing base means Medicare volume — covering 67M Americans with high obesity prevalence — could extend its top-line growth runway without requiring new approvals or pipeline risk.
The $50/month Medicare cap and IRA reimbursement pressure could compress LLY's GLP-1 average selling prices, meaning unit volume gains may not translate proportionally to revenue growth, a genuine risk for a stock priced at a premium to its current 31.7% net margin.
The house read
Leans bullLLY and AMGN face a demand-expansion event with Medicare GLP-1 coverage starting July 1 — the question is whether volume upside outweighs IRA-driven reimbursement compression on Lilly's dominant franchise.
Wrong ifIRA-mandated Medicare price negotiation could compress LLY's realized GLP-1 ASPs materially, and if Q3 volume uptake disappoints vs. elevated buy-side expectations, the stock could retrace sharply given its premium valuation multiple.
Published read · research, not advice